Multiple cellular macromolecules and signaling pathways

The term Multiple cellular macromolecules and signaling pathways is a broad pharmacological classification rather than a discrete molecular target. This designation is typically applied to therapeutic agents—such as photodynamic sensitizers, certain cytotoxic compounds, or complex botanical mixtures—that exert their effects through non-specific interactions with various cellular constituents, including DNA, RNA, proteins, and phospholipids (AdisInsight, 2024). By affecting multiple components simultaneously, these agents trigger a cascade of events across diverse signaling pathways, often leading to systemic biological outcomes like oxidative stress, cell cycle arrest, or apoptosis (National Cancer Institute, 2023). While this multi-target approach can be effective in treating heterogeneous diseases like advanced malignancies or localized infections, it is frequently associated with a higher risk of off-target toxicity and a lack of clear dose-response relationships for specific pathways. Consequently, drugs in this category are often evaluated based on their overall physiological impact and clinical efficacy rather than their affinity for a single receptor or enzyme (ClinicalTrials.gov, 2024). From a drug development perspective, this category presents significant challenges in establishing precise structure-activity relationships and identifying specific predictive biomarkers for patient stratification (PubMed, 2022).

Other names

Multi-target mechanismPleiotropic cellular targetsNon-specific molecular targetsMultiple targets

Non-specific interaction with and damage to various cellular macromolecules, including DNA, proteins, and lipids, which results in the simultaneous modulation or disruption of multiple signaling pathways (AdisInsight, 2024; StatPearls, 2023).